Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antioxidant Activity of Lutein/Zeaxanthin in Premature Newborns
NCT03340103Withdrawn
- Sponsor
- Sooft Italia
- Start
- Oct 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in retinopathy of prematurity (ROP), Intraventricular hemorrhage (IVH), bronchopulmonary dysplasia (BPD) and 1 more comparing Lutein/Zeaxanthin with Placebo (2 arms). Primary endpoints: Change of the lutein's antioxidant power at 30 days and Change of the premature newborns' oxidative stress at 30 days. Planned start Oct 2018; status: withdrawn.
02
Drugs
lutein
03
Conditions
retinopathy of prematurity (ROP)Intraventricular hemorrhage (IVH)bronchopulmonary dysplasia (BPD)necrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on NCT03340103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03340103.